Stocktoria
ARDELYX, INC. ARDX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-06-19
ARDELYX, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $407.3M | $333.6M | $124.5M | $52.2M | $10.1M |
| R&D expense | $71.5M | $52.3M | $35.5M | $35.2M | $91.1M |
| SG&A expense | $337.2M | $258.7M | $134.4M | $76.6M | $72.3M |
| Operating income | -$41.0M | -$27.9M | -$63.3M | -$63.8M | -$154.3M |
| Interest expense | — | — | $5.0M | $3.4M | $4.5M |
| Income tax | $969,000 | $266,000 | $547,000 | $8,000 | $4,000 |
| Net income | -$61.6M | -$39.1M | -$66.1M | -$67.2M | -$158.2M |
| EPS (diluted) | $-0.26 | $-0.17 | $-0.30 | $-0.42 | $-1.52 |
| Operating cash flow | -$42.5M | -$44.8M | -$89.7M | -$70.0M | -$152.6M |
| Free cash flow | -$44.0M | -$45.8M | -$90.1M | -$70.1M | -$154.4M |
| Cash & equivalents | $68.0M | $64.9M | $21.5M | $96.1M | $72.4M |
| Inventory | $123.1M | $91.2M | $49.5M | $28.3M | $0 |
| Total assets | $501.6M | $435.8M | $297.6M | $190.1M | $149.9M |
| Total liabilities | $334.7M | $262.5M | $130.8M | $91.7M | $67.3M |
| Shareholders' equity | $166.9M | $173.3M | $166.8M | $98.3M | $82.6M |
Source: SEC EDGAR filings · CIK 0001437402 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.